Asset profile
IBI356
Monoclonal antibody
Evidence outlook · lead readout
NCT06193434 · Healthy Participants, Atopic Dermatitis Patients
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06193434: This is a randomized, blinded study with both a placebo and an active comparator (dupilumab), which is a sound design, but its primary measure is safety monitoring rather than a skin-disease severity outcome, and no results have been posted yet.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
June 2027 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.